Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBITDA: 2014-2024

Historic EBITDA for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.4 million.

  • Viking Therapeutics' EBITDA fell 329.01% to -$90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238.7 million, marking a year-over-year decrease of 147.02%. This contributed to the annual value of -$110.4 million for FY2024, which is 29.56% down from last year.
  • Per Viking Therapeutics' latest filing, its EBITDA stood at -$110.4 million for FY2024, which was down 29.56% from -$85.2 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' EBITDA ranged from a high of -$39.6 million in FY2020 and a low of -$110.4 million during FY2024.
  • For the 3-year period, Viking Therapeutics' EBITDA averaged around -$88.3 million, with its median value being -$85.2 million (2023).
  • Data for Viking Therapeutics' EBITDA shows a maximum YoY slumped of 56.10% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Viking Therapeutics' EBITDA stood at -$39.6 million in 2020, then tumbled by 40.25% to -$55.5 million in 2021, then dropped by 25.11% to -$69.4 million in 2022, then declined by 22.71% to -$85.2 million in 2023, then fell by 29.56% to -$110.4 million in 2024.